Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Influenza

  Free Subscription


Articles published in Cell

Retrieve available abstracts of 159 articles:
HTML format



Single Articles


    November 2021
  1. PAYNE RP, Longet S, Austin JA, Skelly DT, et al
    Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.
    Cell. 2021;184:5699-5714.
    PubMed     Abstract available


    October 2021
  2. CROSS G, Ho JSY, Zacharias W, Jeyasekharan AD, et al
    Emergency drug use in a pandemic: Harsh lessons from COVID-19.
    Cell. 2021;184:5497-5500.
    PubMed     Abstract available



  3. Persistent progress.
    Cell. 2021;184:5293-5296.
    PubMed     Abstract available


  4. SHAPIRO L, Losick R
    Delivering the message: How a novel technology enabled the rapid development of effective vaccines.
    Cell. 2021;184:5271-5274.
    PubMed     Abstract available


    September 2021
  5. MARTIN DP, Weaver S, Tegally H, San JE, et al
    The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages.
    Cell. 2021;184:5189-5200.
    PubMed     Abstract available


  6. CEVIK M, Grubaugh ND, Iwasaki A, Openshaw P, et al
    COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.
    Cell. 2021;184:5077-5081.
    PubMed     Abstract available


  7. JACKSON B, Boni MF, Bull MJ, Colleran A, et al
    Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic.
    Cell. 2021;184:5179-5188.
    PubMed     Abstract available


  8. ZELLER M, Gangavarapu K, Anderson C, Smither AR, et al
    Emergence of an early SARS-CoV-2 epidemic in the United States.
    Cell. 2021;184:4939-4952.
    PubMed     Abstract available


  9. SPOSITO B, Broggi A, Pandolfi L, Crotta S, et al
    The interferon landscape along the respiratory tract impacts the severity of COVID-19.
    Cell. 2021;184:4953-4968.
    PubMed     Abstract available


  10. HOLMES EC, Goldstein SA, Rasmussen AL, Robertson DL, et al
    The origins of SARS-CoV-2: A critical review.
    Cell. 2021;184:4848-4856.
    PubMed     Abstract available


  11. ZIEGLER CGK, Miao VN, Owings AH, Navia AW, et al
    Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19.
    Cell. 2021;184:4713-4733.
    PubMed     Abstract available


    August 2021
  12. KARLSSON EA, Duong V
    The continuing search for the origins of SARS-CoV-2.
    Cell. 2021;184:4373-4374.
    PubMed     Abstract available


  13. KANG L, He G, Sharp AK, Wang X, et al
    A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation.
    Cell. 2021;184:4392-4400.
    PubMed     Abstract available


  14. NATHAN A, Rossin EJ, Kaseke C, Park RJ, et al
    Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses.
    Cell. 2021;184:4401-4413.
    PubMed     Abstract available


  15. ZHOU H, Ji J, Chen X, Bi Y, et al
    Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses.
    Cell. 2021;184:4380-4391.
    PubMed     Abstract available


  16. LIU C, Ginn HM, Dejnirattisai W, Supasa P, et al
    Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
    Cell. 2021;184:4220-4236.
    PubMed     Abstract available


  17. LI D, Edwards RJ, Manne K, Martinez DR, et al
    In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.
    Cell. 2021;184:4203-4219.
    PubMed     Abstract available


    July 2021
  18. RESCIGNO M
    Unraveling the long-term effect of influenza vaccines.
    Cell. 2021;184:3845-3847.
    PubMed     Abstract available


  19. WEINGARTEN-GABBAY S, Klaeger S, Sarkizova S, Pearlman LR, et al
    Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs.
    Cell. 2021;184:3962-3980.
    PubMed     Abstract available


  20. COPIN R, Baum A, Wloga E, Pascal KE, et al
    The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.
    Cell. 2021;184:3949-3961.
    PubMed     Abstract available


    June 2021
  21. YAN L, Yang Y, Li M, Zhang Y, et al
    Coupling of N7-methyltransferase and 3'-5' exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading.
    Cell. 2021;184:3474-3485.
    PubMed     Abstract available


  22. LIU K, Pan X, Li L, Yu F, et al
    Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species.
    Cell. 2021;184:3438-3451.
    PubMed     Abstract available


  23. LIU Y, Soh WT, Kishikawa JI, Hirose M, et al
    An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.
    Cell. 2021;184:3452-3466.
    PubMed     Abstract available


  24. HE X, Chandrashekar A, Zahn R, Wegmann F, et al
    Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques.
    Cell. 2021;184:3467-3473.
    PubMed     Abstract available


  25. HAO Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, et al
    Integrated analysis of multimodal single-cell data.
    Cell. 2021;184:3573-3587.
    PubMed     Abstract available


  26. DENG X, Garcia-Knight MA, Khalid MM, Servellita V, et al
    Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.
    Cell. 2021;184:3426-3437.
    PubMed     Abstract available


  27. WIMMERS F, Donato M, Kuo A, Ashuach T, et al
    The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination.
    Cell. 2021 Jun 22. pii: S0092-8674(21)00692-9. doi: 10.1016/j.cell.2021.
    PubMed     Abstract available


  28. CORTI D, Purcell LA, Snell G, Veesler D, et al
    Tackling COVID-19 with neutralizing monoclonal antibodies.
    Cell. 2021;184:3086-3108.
    PubMed     Abstract available


  29. SCHEID JF, Barnes CO, Eraslan B, Hudak A, et al
    B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV.
    Cell. 2021;184:3205-3221.
    PubMed     Abstract available


  30. ASARNOW D, Wang B, Lee WH, Hu Y, et al
    Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia.
    Cell. 2021;184:3192-3204.
    PubMed     Abstract available


    May 2021
  31. BAUMER Y, Powell-Wiley TM
    Interdisciplinary approaches are fundamental to decode the biology of adversity.
    Cell. 2021;184:2797-2801.
    PubMed     Abstract available


  32. GARRETT ME, Galloway J, Chu HY, Itell HL, et al
    High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies.
    Cell. 2021;184:2927-2938.
    PubMed     Abstract available


  33. DEJNIRATTISAI W, Zhou D, Supasa P, Liu C, et al
    Antibody evasion by the P.1 strain of SARS-CoV-2.
    Cell. 2021;184:2939-2954.
    PubMed     Abstract available


  34. WILLIAMS WB, Meyerhoff RR, Edwards RJ, Li H, et al
    Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies.
    Cell. 2021 May 18. pii: S0092-8674(21)00577-8. doi: 10.1016/j.cell.2021.
    PubMed     Abstract available


  35. ALPERT T, Brito AF, Lasek-Nesselquist E, Rothman J, et al
    Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States.
    Cell. 2021;184:2595-2604.
    PubMed     Abstract available


  36. WASHINGTON NL, Gangavarapu K, Zeller M, Bolze A, et al
    Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States.
    Cell. 2021;184:2587-2594.
    PubMed     Abstract available


  37. HO JSY, Mok BW, Campisi L, Jordan T, et al
    TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.
    Cell. 2021;184:2618-2632.
    PubMed     Abstract available


  38. CLARK SA, Clark LE, Pan J, Coscia A, et al
    SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms.
    Cell. 2021;184:2605-2617.
    PubMed     Abstract available


    April 2021
  39. LEBLANC EV, Colpitts CC
    SARS-CoV-2 RNA: Exclusive friends and common foes.
    Cell. 2021;184:2276-2278.
    PubMed     Abstract available


  40. BOEHM JS
    The power of parent scientists.
    Cell. 2021;184:2263-2270.
    PubMed     Abstract available


  41. HOFFMANN M, Arora P, Gross R, Seidel A, et al
    SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
    Cell. 2021;184:2384-2393.
    PubMed     Abstract available


  42. SURYADEVARA N, Shrihari S, Gilchuk P, VanBlargan LA, et al
    Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.
    Cell. 2021;184:2316-2331.
    PubMed     Abstract available


  43. FABIUS JM, Krogan NJ
    Creating collaboration by breaking down scientific barriers.
    Cell. 2021;184:2271-2275.
    PubMed     Abstract available


  44. MCCALLUM M, De Marco A, Lempp FA, Tortorici MA, et al
    N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.
    Cell. 2021;184:2332-2347.
    PubMed     Abstract available


  45. GARCIA-BELTRAN WF, Lam EC, St Denis K, Nitido AD, et al
    Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
    Cell. 2021;184:2372-2383.
    PubMed     Abstract available


  46. FLYNN RA, Belk JA, Qi Y, Yasumoto Y, et al
    Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions.
    Cell. 2021;184:2394-2411.
    PubMed     Abstract available


  47. ZHOU D, Dejnirattisai W, Supasa P, Liu C, et al
    Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
    Cell. 2021;184:2348-2361.
    PubMed     Abstract available



  48. The origins of viral infection sleuth.
    Cell. 2021;184:1960-1961.
    PubMed     Abstract available


  49. SCHNEIDER JL, Rowe JH, Garcia-de-Alba C, Kim CF, et al
    The aging lung: Physiology, disease, and immunity.
    Cell. 2021;184:1990-2019.
    PubMed     Abstract available


  50. MILLS RJ, Humphrey SJ, Fortuna PRJ, Lor M, et al
    BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection.
    Cell. 2021;184:2167-2182.
    PubMed     Abstract available


  51. DEJNIRATTISAI W, Zhou D, Ginn HM, Duyvesteyn HME, et al
    The antigenic anatomy of SARS-CoV-2 receptor binding domain.
    Cell. 2021;184:2183-2200.
    PubMed     Abstract available


  52. SUPASA P, Zhou D, Dejnirattisai W, Liu C, et al
    Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
    Cell. 2021;184:2201-2211.
    PubMed     Abstract available


  53. YEUNG ML, Teng JLL, Jia L, Zhang C, et al
    Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system.
    Cell. 2021;184:2212-2228.
    PubMed     Abstract available


  54. ZHANG X, Liu Y, Liu J, Bailey AL, et al
    A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence.
    Cell. 2021;184:2229-2238.
    PubMed     Abstract available


  55. PEIRIS JSM
    One world, one health.
    Cell. 2021;184:1956-1959.
    PubMed     Abstract available


  56. SCHULTZE JL, Aschenbrenner AC
    COVID-19 and the human innate immune system.
    Cell. 2021;184:1671-1692.
    PubMed     Abstract available


  57. YU B, Qi Y, Li R, Shi Q, et al
    B cell-specific XIST complex enforces X-inactivation and restrains atypical B cells.
    Cell. 2021;184:1790-1803.
    PubMed     Abstract available


  58. LIU C, Martins AJ, Lau WW, Rachmaninoff N, et al
    Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19.
    Cell. 2021;184:1836-1857.
    PubMed     Abstract available


  59. WINKLER ES, Gilchuk P, Yu J, Bailey AL, et al
    Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.
    Cell. 2021;184:1804-1820.
    PubMed     Abstract available


  60. ANDREANO E, Nicastri E, Paciello I, Pileri P, et al
    Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.
    Cell. 2021;184:1821-1835.
    PubMed     Abstract available


  61. REN X, Wen W, Fan X, Hou W, et al
    COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas.
    Cell. 2021;184:1895-1913.
    PubMed     Abstract available


  62. SUN L, Li P, Ju X, Rao J, et al
    In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs.
    Cell. 2021;184:1865-1883.
    PubMed     Abstract available


  63. ANDERSON EM, Goodwin EC, Verma A, Arevalo CP, et al
    Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection.
    Cell. 2021;184:1858-1864.
    PubMed     Abstract available


    March 2021
  64. GEBRE MS, Brito LA, Tostanoski LH, Edwards DK, et al
    Novel approaches for vaccine development.
    Cell. 2021;184:1589-1603.
    PubMed     Abstract available


  65. SANDRONE S, Scott G, Anderson WJ, Musunuru K, et al
    Active learning-based STEM education for in-person and online learning.
    Cell. 2021;184:1409-1414.
    PubMed     Abstract available



  66. Scientific misinformation: A perfect storm, missteps, and moving forward.
    Cell. 2021;184:1402-1406.
    PubMed     Abstract available


  67. TOPOL EJ
    Messenger RNA vaccines against SARS-CoV-2.
    Cell. 2021;184:1401.
    PubMed     Abstract available


  68. PILLON NJ, Loos RJF, Marshall SM, Zierath JR, et al
    Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care.
    Cell. 2021;184:1530-1544.
    PubMed     Abstract available


  69. MANN ME, Hall LJ, Dulvy NK
    Scientific impact in a changing world.
    Cell. 2021;184:1407-1408.
    PubMed     Abstract available


  70. THOMSON EC, Rosen LE, Shepherd JG, Spreafico R, et al
    Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.
    Cell. 2021;184:1171-1187.
    PubMed     Abstract available


  71. GRUBAUGH ND, Hodcroft EB, Fauver JR, Phelan AL, et al
    Public health actions to control new SARS-CoV-2 variants.
    Cell. 2021;184:1127-1132.
    PubMed     Abstract available


  72. BROUWER PJM, Brinkkemper M, Maisonnasse P, Dereuddre-Bosquet N, et al
    Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection.
    Cell. 2021;184:1188-1200.
    PubMed     Abstract available


  73. SOKAL A, Chappert P, Barba-Spaeth G, Roeser A, et al
    Maturation and persistence of the anti-SARS-CoV-2 memory B cell response.
    Cell. 2021;184:1201-1213.
    PubMed     Abstract available


    February 2021
  74. LI Q, Nie J, Wu J, Zhang L, et al
    SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.
    Cell. 2021 Feb 23. pii: S0092-8674(21)00231-2. doi: 10.1016/j.cell.2021.
    PubMed     Abstract available


  75. SETTE A, Crotty S
    Adaptive immunity to SARS-CoV-2 and COVID-19.
    Cell. 2021;184:861-880.
    PubMed     Abstract available


  76. NIE X, Qian L, Sun R, Huang B, et al
    Multi-organ proteomic landscape of COVID-19 autopsies.
    Cell. 2021;184:775-791.
    PubMed     Abstract available


  77. ATYEO C, Pullen KM, Bordt EA, Fischinger S, et al
    Compromised SARS-CoV-2-specific placental antibody transfer.
    Cell. 2021;184:628-642.
    PubMed     Abstract available


    January 2021
  78. GARCIA-BELTRAN WF, Lam EC, Astudillo MG, Yang D, et al
    COVID-19-neutralizing antibodies predict disease severity and survival.
    Cell. 2021;184:476-488.
    PubMed     Abstract available


  79. HOANG TN, Pino M, Boddapati AK, Viox EG, et al
    Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
    Cell. 2021;184:460-475.
    PubMed     Abstract available



  80. What happens next.
    Cell. 2021;184:291-292.
    PubMed    


  81. HOFFMANN HH, Schneider WM, Rozen-Gagnon K, Miles LA, et al
    TMEM41B Is a Pan-flavivirus Host Factor.
    Cell. 2021;184:133-148.
    PubMed     Abstract available


  82. WANG R, Simoneau CR, Kulsuptrakul J, Bouhaddou M, et al
    Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses.
    Cell. 2021;184:106-119.
    PubMed     Abstract available


  83. RODDA LB, Netland J, Shehata L, Pruner KB, et al
    Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19.
    Cell. 2021;184:169-183.
    PubMed     Abstract available


  84. KARKI R, Sharma BR, Tuladhar S, Williams EP, et al
    Synergism of TNF-alpha and IFN-gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes.
    Cell. 2021;184:149-168.
    PubMed     Abstract available


  85. VOLZ E, Hill V, McCrone JT, Price A, et al
    Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity.
    Cell. 2021;184:64-75.
    PubMed     Abstract available


  86. DANILOSKI Z, Jordan TX, Wessels HH, Hoagland DA, et al
    Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells.
    Cell. 2021;184:92-105.
    PubMed     Abstract available


  87. WEI J, Alfajaro MM, DeWeirdt PC, Hanna RE, et al
    Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection.
    Cell. 2021;184:76-91.
    PubMed     Abstract available


    December 2020
  88. AVANZATO VA, Matson MJ, Seifert SN, Pryce R, et al
    Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer.
    Cell. 2020;183:1901-1912.
    PubMed     Abstract available


  89. ZOHAR T, Loos C, Fischinger S, Atyeo C, et al
    Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality.
    Cell. 2020;183:1508-1519.
    PubMed     Abstract available


  90. SU Y, Chen D, Yuan D, Lausted C, et al
    Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19.
    Cell. 2020;183:1479-1495.
    PubMed     Abstract available


  91. CHEN Y, Zuiani A, Fischinger S, Mullur J, et al
    Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production.
    Cell. 2020;183:1496-1507.
    PubMed     Abstract available


  92. GHOSH S, Dellibovi-Ragheb TA, Kerviel A, Pak E, et al
    beta-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway.
    Cell. 2020;183:1520-1535.
    PubMed     Abstract available


    November 2020
  93. WALLS AC, Fiala B, Schafer A, Wrenn S, et al
    Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.
    Cell. 2020;183:1367-1382.
    PubMed     Abstract available


  94. MECKIFF BJ, Ramirez-Suastegui C, Fajardo V, Chee SJ, et al
    Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19.
    Cell. 2020;183:1340-1353.
    PubMed     Abstract available


  95. BANERJEE AK, Blanco MR, Bruce EA, Honson DD, et al
    SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses.
    Cell. 2020;183:1325-1339.
    PubMed     Abstract available


  96. AID M, Busman-Sahay K, Vidal SJ, Maliga Z, et al
    Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques.
    Cell. 2020;183:1354-1366.
    PubMed     Abstract available


  97. KREYE J, Reincke SM, Kornau HC, Sanchez-Sendin E, et al
    A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
    Cell. 2020;183:1058-1069.
    PubMed     Abstract available


  98. LEIST SR, Dinnon KH 3rd, Schafer A, Tse LV, et al
    A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice.
    Cell. 2020;183:1070-1085.
    PubMed     Abstract available


  99. RYDYZNSKI MODERBACHER C, Ramirez SI, Dan JM, Grifoni A, et al
    Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.
    Cell. 2020;183:996-1012.
    PubMed     Abstract available


  100. PICCOLI L, Park YJ, Tortorici MA, Czudnochowski N, et al
    Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
    Cell. 2020;183:1024-1042.
    PubMed     Abstract available


  101. GRUBER CN, Patel RS, Trachtman R, Lepow L, et al
    Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C).
    Cell. 2020;183:982-995.
    PubMed     Abstract available


  102. CLAUSEN TM, Sandoval DR, Spliid CB, Pihl J, et al
    SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.
    Cell. 2020;183:1043-1057.
    PubMed     Abstract available


  103. CONSIGLIO CR, Cotugno N, Sardh F, Pou C, et al
    The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19.
    Cell. 2020;183:968-981.
    PubMed     Abstract available


    October 2020
  104. YURKOVETSKIY L, Wang X, Pascal KE, Tomkins-Tinch C, et al
    Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.
    Cell. 2020;183:739-751.
    PubMed     Abstract available


  105. MUKHERJEE S
    Before Virus, After Virus: A Reckoning.
    Cell. 2020;183:308-314.
    PubMed     Abstract available


  106. IWASAKI A, Omer SB
    Why and How Vaccines Work.
    Cell. 2020;183:290-295.
    PubMed     Abstract available


  107. GOLDSTEIN JL
    The Spanish 1918 Flu and the COVID-19 Disease: The Art of Remembering and Foreshadowing Pandemics.
    Cell. 2020;183:285-289.
    PubMed     Abstract available


  108. LI W, Schafer A, Kulkarni SS, Liu X, et al
    High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models.
    Cell. 2020;183:429-441.
    PubMed     Abstract available


  109. SEKINE T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, et al
    Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.
    Cell. 2020;183:158-168.
    PubMed     Abstract available


  110. AU L, Boos LA, Swerdlow A, Byrne F, et al
    Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study.
    Cell. 2020;183:4-10.
    PubMed     Abstract available


  111. CANETE PF, Vinuesa CG
    COVID-19 Makes B Cells Forget, but T Cells Remember.
    Cell. 2020;183:13-15.
    PubMed     Abstract available


  112. HASSAN AO, Kafai NM, Dmitriev IP, Fox JM, et al
    A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2.
    Cell. 2020;183:169-184.
    PubMed     Abstract available


  113. IADECOLA C, Anrather J, Kamel H
    Effects of COVID-19 on the Nervous System.
    Cell. 2020;183:16-27.
    PubMed     Abstract available


  114. KANEKO N, Kuo HH, Boucau J, Farmer JR, et al
    Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19.
    Cell. 2020;183:143-157.
    PubMed     Abstract available


    September 2020
  115. SILVIN A, Chapuis N, Dunsmore G, Goubet AG, et al
    Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.
    Cell. 2020;182:1401-1418.
    PubMed     Abstract available


  116. COLUBRI A, Kemball M, Sani K, Boehm C, et al
    Preventing Outbreaks through Interactive, Experiential Real-Life Simulations.
    Cell. 2020;182:1366-1371.
    PubMed     Abstract available


  117. SCHULTE-SCHREPPING J, Reusch N, Paclik D, Bassler K, et al
    Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment.
    Cell. 2020;182:1419-1440.
    PubMed     Abstract available


  118. DU S, Cao Y, Zhu Q, Yu P, et al
    Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
    Cell. 2020 Sep 14. pii: S0092-8674(20)31232-0. doi: 10.1016/j.cell.2020.
    PubMed     Abstract available


  119. MORENS DM, Fauci AS
    Emerging Pandemic Diseases: How We Got to COVID-19.
    Cell. 2020;182:1077-1092.
    PubMed     Abstract available


    August 2020
  120. GRUBAUGH ND, Hanage WP, Rasmussen AL
    Making Sense of Mutation: What D614G Means for the COVID-19 Pandemic Remains Unclear.
    Cell. 2020;182:794-795.
    PubMed     Abstract available


  121. KORBER B, Fischer WM, Gnanakaran S, Yoon H, et al
    Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.
    Cell. 2020;182:812-827.
    PubMed     Abstract available


  122. KREER C, Zehner M, Weber T, Ercanoglu MS, et al
    Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.
    Cell. 2020;182:843-854.
    PubMed     Abstract available


  123. BARNES CO, West AP Jr, Huey-Tubman KE, Hoffmann MAG, et al
    Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.
    Cell. 2020;182:828-842.
    PubMed     Abstract available


  124. GEITMANN A
    Travel Less. Make It Worthwhile.
    Cell. 2020;182:790-793.
    PubMed     Abstract available


  125. WANG H, Zhang Y, Huang B, Deng W, et al
    Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.
    Cell. 2020;182:713-721.
    PubMed     Abstract available


  126. DAI L, Zheng T, Xu K, Han Y, et al
    A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
    Cell. 2020;182:722-733.
    PubMed     Abstract available


  127. BOUHADDOU M, Memon D, Meyer B, White KM, et al
    The Global Phosphorylation Landscape of SARS-CoV-2 Infection.
    Cell. 2020;182:685-712.
    PubMed     Abstract available


  128. SUN J, Zhuang Z, Zheng J, Li K, et al
    Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment.
    Cell. 2020;182:734-743.
    PubMed     Abstract available


  129. HASSAN AO, Case JB, Winkler ES, Thackray LB, et al
    A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.
    Cell. 2020;182:744-753.
    PubMed     Abstract available


    July 2020
  130. EINAV T, Gentles LE, Bloom JD
    SnapShot: Influenza by the Numbers.
    Cell. 2020;182:532-532.
    PubMed     Abstract available


  131. JIANG RD, Liu MQ, Chen Y, Shan C, et al
    Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2.
    Cell. 2020;182:50-58.
    PubMed     Abstract available


  132. SHEN B, Yi X, Sun Y, Bi X, et al
    Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.
    Cell. 2020;182:59-72.
    PubMed     Abstract available


  133. CAO Y, Su B, Guo X, Sun W, et al
    Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.
    Cell. 2020;182:73-84.
    PubMed     Abstract available


  134. JOYCE MG, Wheatley AK, Modjarrad K
    Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks.
    Cell. 2020;182:7-9.
    PubMed     Abstract available


    June 2020
  135. SEMPOWSKI GD, Saunders KO, Acharya P, Wiehe KJ, et al
    Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19.
    Cell. 2020;181:1458-1463.
    PubMed     Abstract available


  136. BOST P, Giladi A, Liu Y, Bendjelal Y, et al
    Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients.
    Cell. 2020;181:1475-1488.
    PubMed     Abstract available


  137. GRIFONI A, Weiskopf D, Ramirez SI, Mateus J, et al
    Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
    Cell. 2020;181:1489-1501.
    PubMed     Abstract available


  138. ZEGGINI E, Baumann M, Gotz M, Herzig S, et al
    Biomedical Research Goes Viral: Dangers and Opportunities.
    Cell. 2020;181:1189-1193.
    PubMed     Abstract available


  139. ZHANG K, Liu X, Shen J, Li Z, et al
    Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography.
    Cell. 2020;181:1423-1433.
    PubMed     Abstract available


  140. CASANOVA JL, Su HC
    A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection.
    Cell. 2020;181:1194-1199.
    PubMed     Abstract available


    May 2020
  141. NETEA MG, Giamarellos-Bourboulis EJ, Dominguez-Andres J, Curtis N, et al
    Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection.
    Cell. 2020;181:969-977.
    PubMed     Abstract available


  142. BLANCO-MELO D, Nilsson-Payant BE, Liu WC, Uhl S, et al
    Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.
    Cell. 2020;181:1036-1045.
    PubMed     Abstract available


  143. ZIEGLER CGK, Allon SJ, Nyquist SK, Mbano IM, et al
    SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.
    Cell. 2020;181:1016-1035.
    PubMed     Abstract available


  144. FAUVER JR, Petrone ME, Hodcroft EB, Shioda K, et al
    Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States.
    Cell. 2020;181:990-996.
    PubMed     Abstract available


  145. WRAPP D, De Vlieger D, Corbett KS, Torres GM, et al
    Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.
    Cell. 2020;181:1004-1015.
    PubMed     Abstract available


  146. LU J, du Plessis L, Liu Z, Hill V, et al
    Genomic Epidemiology of SARS-CoV-2 in Guangdong Province, China.
    Cell. 2020;181:997-1003.
    PubMed     Abstract available


  147. HOU YJ, Okuda K, Edwards CE, Martinez DR, et al
    SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract.
    Cell. 2020 May 27. pii: S0092-8674(20)30675-9. doi: 10.1016/j.cell.2020.
    PubMed     Abstract available


  148. OBERFELD B, Achanta A, Carpenter K, Chen P, et al
    SnapShot: COVID-19.
    Cell. 2020;181:954-954.
    PubMed     Abstract available


  149. MONTEIL V, Kwon H, Prado P, Hagelkruys A, et al
    Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.
    Cell. 2020;181:905-913.
    PubMed     Abstract available


    April 2020
  150. ABBOTT TR, Dhamdhere G, Liu Y, Lin X, et al
    Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.
    Cell. 2020 Apr 29. pii: S0092-8674(20)30483-9. doi: 10.1016/j.cell.2020.
    PubMed     Abstract available


  151. WANDZIK JM, Kouba T, Karuppasamy M, Pflug A, et al
    A Structure-Based Model for the Complete Transcription Cycle of Influenza Polymerase.
    Cell. 2020 Apr 16. pii: S0092-8674(20)30389-5. doi: 10.1016/j.cell.2020.
    PubMed     Abstract available



  152. COVID-19: Navigating Uncertainties Together.
    Cell. 2020;181:209-210.
    PubMed    


  153. ZHANG YZ, Holmes EC
    A Genomic Perspective on the Origin and Emergence of SARS-CoV-2.
    Cell. 2020;181:223-227.
    PubMed     Abstract available


  154. HOFFMANN M, Kleine-Weber H, Schroeder S, Kruger N, et al
    SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
    Cell. 2020;181:271-280.
    PubMed     Abstract available


    March 2020
  155. ZHANG T, Yin C, Boyd DF, Quarato G, et al
    Influenza Virus Z-RNAs Induce ZBP1-Mediated Necroptosis.
    Cell. 2020;180:1115-1129.
    PubMed     Abstract available



  156. The Novel Coronavirus Outbreak: What We Know and What We Don't.
    Cell. 2020;180:1034-1036.
    PubMed    


    January 2020
  157. VAHEY MD, Fletcher DA
    Low-Fidelity Assembly of Influenza A Virus Promotes Escape from Host Cells.
    Cell. 2020;180:205.
    PubMed    


    May 2019
  158. GARCIA-SASTRE A
    Snatch-and-Grab Inhibitors to Fight the Flu.
    Cell. 2019;177:1367.
    PubMed     Abstract available


    January 2019
  159. MARTIN BE, Brooke CB
    Flu Shows the Power of Diversity.
    Cell. 2019;176.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: